J. Gan

R. Seeger, R. Reisfeld, T. Chew, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Ex Vivo Evaluation of Anti-EpCAM Immunocytokine huKS-IL2 in Ovarian Cancer

S. Gillies, J. Harter, J. Connor, 2004, Journal of immunotherapy.

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.

K. Matthay, R. Seeger, G. Reaman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.

R. Bechhofer, B. Storer, J. Schiller, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma.

B. Storer, J. Schiller, M. Albertini, 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

R. Reisfeld, J. Hank, J. Gan, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients.

R. Bechhofer, B. Storer, J. Schiller, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma

KyungMann Kim, S. Gillies, J. Pandey, 2020, Journal for ImmunoTherapy of Cancer.

Phase II trial of hu14.18-IL2 for patients with metastatic melanoma

KyungMann Kim, J. Eickhoff, M. Albertini, 2012, Cancer Immunology, Immunotherapy.

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma

D. Mahvi, KyungMann Kim, M. Albertini, 2006, Cancer Immunology, Immunotherapy.

Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

E. Ranheim, D. Mahvi, KyungMann Kim, 2018, Cancer Immunology, Immunotherapy.

A Phase I Trial of Immunocytokine HU14.18-IL2 in Children with Recurrent or Refractory Neuroblastoma and Other GD2 Positive Malignancies: A Study of the Children's Oncology Group

K. Matthay, P. Adamson, R. Seeger, 2004 .

A Phase I Study of Immunization Using Particle-Mediated Epidermal Delivery of Genes for gp100 and GM-CSF into Uninvolved Skin of Melanoma Patients

D. Mahvi, KyungMann Kim, M. Albertini, 2007, Clinical Cancer Research.

Phase I/IB Study of Immunization with Autologous Tumor Cells Transfected with the GM-CSF Gene by Particle-Mediated Transfer in Patients with Melanoma or Sarcoma University of Wisconsin, Madison, Wisconsin

J. Schiller, N. Yang, J. Heiner, 1997 .

Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins

S. Gillies, J. Hank, P. Sondel, 1999, Clinical Diagnostic Laboratory Immunology.

Expression of a tumor-reactive antibody-interleukin 2 fusion protein after in vivo particle-mediated gene delivery.

J. Schlom, S. Kashmiri, N. Yang, 1995, Cancer gene therapy.

Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia.

S. Feig, T. Tjoa, B. Lange, 2000, The cancer journal from Scientific American.

Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention

E. Ranheim, KyungMann Kim, S. Gillies, 2012, The Journal of Immunology.

Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.

S. Helfand, J. Hank, P. Sondel, 1996, Cellular immunology.

Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.

M. Lindstrom, S. Helfand, J. Hank, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

A. Naranjo, J. Maris, K. Matthay, 2021, Clinical Cancer Research.

Application of monoclonal antibodies for affinity electrophoresis.

J. Gan, J. Bręborowicz, J. Kłosin, 1987, Journal of immunological methods.

Affinity electrophoresis with monoclonal antibodies

P. Waliszewski, J. Gan, J. Bręborowicz, 1987 .

Soluble interleukin‐2 receptor α activation in a Children's Oncology Group randomized trial of interleukin‐2 Therapy for Pediatric Acute Myeloid Leukemia

T. Alonzo, R. Gerbing, B. Lange, 2011, Pediatric blood & cancer.

This information is current as Well As Enhanced IC Retention Involve Both Activated T and NK Cells As Local and Systemic Antitumor Effects That IL-2 (IC) Induces - Intratumoral hu14.18

E. Ranheim, S. Gillies, R. Reisfeld, 2017 .

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.

J. Maris, W. London, R. Seeger, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.